Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | VCP | P55072 | 1/20 | 0.56 |
| ▸ | L3MBTL3 | Q96JM7 | 5/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.49 |
| ▸ | MBTD1 | Q05BQ5 | 2/20 | 0.49 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | AGXT | P21549 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24073827 | 0.86 | L3MBTL3 (0.67) | ADRA2CALDH1A1L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL24774008 | 0.85 | ALDH1A1 (0.59) | ADRA2CALDH1A1VCPL3MBTL3L3MBTL1 | |
| SCHEMBL2635187 | 0.84 | VCP (0.58) | ADRA2CALDH1A1VCPL3MBTL3L3MBTL1 | |
| SCHEMBL448110 | 0.84 | ADRA2C (1.00) | ADRA2CALDH1A1SMN1; SMN2KDM4EGAA | |
| SCHEMBL156422 | 0.83 | ALDH1A1 (0.68) | ADRA2CALDH1A1VCPL3MBTL3L3MBTL1 | |
| SCHEMBL30378754 | 0.82 | TSHR (0.61) | ALDH1A1VCPL3MBTL1SMN1; SMN2KDM4E | |
| SCHEMBL19288664 | 0.82 | TSHR (0.61) | ALDH1A1VCPL3MBTL1SMN1; SMN2KDM4E | |
| SCHEMBL28330181 | 0.82 | L3MBTL1 (0.71) | ALDH1A1VCPL3MBTL3L3MBTL1MBTD1 | |
| Hydrochloric Acid SCHEMBL16209754 | 0.82 | ADRA2C (0.96) | ADRA2CALDH1A1SMN1; SMN2KDM4EGAA | |
| SCHEMBL23122819 | 0.82 | MAPT (0.54) | ADRA2CALDH1A1VCPL3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-10-05 | — | — | US | disclosed |
| WO-2021238827-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | 南京红云生物科技有限公司 | 2021-12-02 | — | — | WO | disclosed |
| US-9487491-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9487491-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2016-11-08 | — | — | US | disclosed |
| EP-2428508-B9 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-04-20 | — | — | EP | disclosed |
| EP-2428508-B1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC (JP) | 2015-12-16 | — | — | EP | disclosed |
| US-8969336-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-8969336-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-18 | — | — | US | disclosed |
| EP-2428508-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2012-03-14 | — | — | EP | disclosed |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | WATERS TECHNOLOGIES CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | WATERS TECHNOLOGIES CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | ADRA2C 4411/4885ALDH1A1 1554/4885VCP 4556/4885 |
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | ADRA2C 3819/4885ALDH1A1 3822/4885VCP 3414/4885 |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | ADRA2C 4411/4885ALDH1A1 1554/4885VCP 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.